Pharmaceutical Takeda Pharmaceutical’s shares edged up 1.2% to 4,278 b close of Tokyo trading today, after the Japanese drug major announced that results from the primary endpoint analysis of the ongoing pivotal Phase III Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial of its dengue vaccine candidate (TAK-003) were published in the New England Journal of Medicine. 7 November 2019